[
  {
    "ts": null,
    "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
    "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
    "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764684031,
      "headline": "Retiring On Dividends: SCHD Vs. Covered Call ETFs",
      "id": 137664425,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2210232423/image_2210232423.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Compare SCHD and covered call ETFs like JEPI for retirement income. Read about which passive income strategy best funds your retirement goals.",
      "url": "https://finnhub.io/api/news?id=7bc44d4c484196bf9999683817fa3de9c53ff6918b0f9411feb48d02865b0202"
    }
  },
  {
    "ts": null,
    "headline": "Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors",
    "summary": "MILLBRAE, Calif., December 02, 2025--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with cutting-edge research to accelerate drug discovery, today announced the election of David W. Meline as an independent director effective November 23, 2025. Mr. Meline is the former Chief Financial Officer at Moderna Inc.",
    "url": "https://finnhub.io/api/news?id=1eb9ed06174f786b4560127d1279a45d4688c291bfefa8321d3af771a3a628c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764680400,
      "headline": "Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors",
      "id": 137662273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "MILLBRAE, Calif., December 02, 2025--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with cutting-edge research to accelerate drug discovery, today announced the election of David W. Meline as an independent director effective November 23, 2025. Mr. Meline is the former Chief Financial Officer at Moderna Inc.",
      "url": "https://finnhub.io/api/news?id=1eb9ed06174f786b4560127d1279a45d4688c291bfefa8321d3af771a3a628c7"
    }
  },
  {
    "ts": null,
    "headline": "A Look at Amgen (AMGN) Valuation After Full FDA Approval and NCCN Guideline Update for IMDELLTRA",
    "summary": "Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small cell lung cancer after platinum-based chemotherapy. The NCCN also updated guidelines and named IMDELLTRA the only Category 1 preferred therapy in this scenario. See our latest analysis for Amgen. Amgen’s momentum has picked up meaningfully this year, with its recent FDA approval for IMDELLTRA building on earlier upbeat news such as robust Q3 earnings and a strong lineup of...",
    "url": "https://finnhub.io/api/news?id=3cd0c0f6980466c0a734295297f05b5a7410904bbea616197462dd0f31400244",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764677534,
      "headline": "A Look at Amgen (AMGN) Valuation After Full FDA Approval and NCCN Guideline Update for IMDELLTRA",
      "id": 137662274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small cell lung cancer after platinum-based chemotherapy. The NCCN also updated guidelines and named IMDELLTRA the only Category 1 preferred therapy in this scenario. See our latest analysis for Amgen. Amgen’s momentum has picked up meaningfully this year, with its recent FDA approval for IMDELLTRA building on earlier upbeat news such as robust Q3 earnings and a strong lineup of...",
      "url": "https://finnhub.io/api/news?id=3cd0c0f6980466c0a734295297f05b5a7410904bbea616197462dd0f31400244"
    }
  },
  {
    "ts": null,
    "headline": "How the Story Behind Amgen Is Shifting After Pipeline and Guidance Updates",
    "summary": "Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target from $318.51 to $322.88. This modest revision comes amid a backdrop of mixed analyst sentiment, with optimism regarding Amgen’s innovative pipeline and stable revenue base being balanced against concerns over patent expiries and the pace of new product adoption. For those closely following Amgen, understanding these updates is key. Keep reading to learn how to track...",
    "url": "https://finnhub.io/api/news?id=0b49c705a297512b3080d67af61cc5047bc23f71531c2798e18f9eb0faf1ccc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764670273,
      "headline": "How the Story Behind Amgen Is Shifting After Pipeline and Guidance Updates",
      "id": 137662275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target from $318.51 to $322.88. This modest revision comes amid a backdrop of mixed analyst sentiment, with optimism regarding Amgen’s innovative pipeline and stable revenue base being balanced against concerns over patent expiries and the pace of new product adoption. For those closely following Amgen, understanding these updates is key. Keep reading to learn how to track...",
      "url": "https://finnhub.io/api/news?id=0b49c705a297512b3080d67af61cc5047bc23f71531c2798e18f9eb0faf1ccc4"
    }
  },
  {
    "ts": null,
    "headline": "Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health",
    "summary": "Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025.",
    "url": "https://finnhub.io/api/news?id=c113091fe11f5578f5dfac5eec5835225610bf1b1466cf0ab4c7f3eac4255ad0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764658800,
      "headline": "Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health",
      "id": 137659151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to Xgeva® (Amgen), following the scheduled expiry of the reference medicine's patent on 27 November 2025.",
      "url": "https://finnhub.io/api/news?id=c113091fe11f5578f5dfac5eec5835225610bf1b1466cf0ab4c7f3eac4255ad0"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Double Up On Right Now",
    "summary": "Investors don't have to worry about dividend cuts with these two stocks.",
    "url": "https://finnhub.io/api/news?id=2bedf1b51eaf10f0fee2a0ea12b92f9a26563a6b67c7852ed4c94a910c55dd64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764650220,
      "headline": "2 Dividend Stocks to Double Up On Right Now",
      "id": 137659044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investors don't have to worry about dividend cuts with these two stocks.",
      "url": "https://finnhub.io/api/news?id=2bedf1b51eaf10f0fee2a0ea12b92f9a26563a6b67c7852ed4c94a910c55dd64"
    }
  }
]